NOAH Compendium

Printed from NOAH Compendium ( (c) Copyright NOAH Compendium 2024. All Rights Reserved.
Date: Monday, April 15, 2024 17:02

Description: Dechra
Release 2.63
Clindabactin® Chewable Tablets
Species: Cats, Dogs
Therapeutic indication: Pharmaceuticals: Antimicrobials: Oral preparations: Tablets
Active ingredient: Clindamycin
Product:Clindabactin® Chewable Tablets
Product index: Clindabactin Chewable Tablets
Qualitative and quantitative composition
Clindabactin 55 mg chewable tablets for cats and dogs:
1 tablet contains: Active substance:
Clindamycin (as clindamycin hydrochloride) 55 mg
Clindabactin 220 mg chewable tablets for dogs:
1 tablet contains: Active substance:
Clindamycin (as clindamycin hydrochloride) 220 mg
Clindabactin 440 mg chewable tablets for dogs:
1 tablet contains: Active substance:
Clindamycin (as clindamycin hydrochloride) 440 mg
Pharmaceutical form
Chewable tablet.
Light brown with brown spots, round and convex chewable flavoured 9 mm (55 mg), 13 mm (220 mg), 18 mm (440 mg) tablet with a cross-shaped break line on one side.
Tablets can be divided into 2 or 4 equal parts.
Clinical particulars
Target species
Clindabactin 55 mg: Cats and Dogs
Clindabactin 220 mg and 440 mg: Dogs
Indications for use
For the treatment of infected wounds and abscesses, and oral cavity infections including periodontal disease, caused by or associated with Staphylococcus spp., Streptococcus spp. (except Streptococcus faecalis), Bacteroides spp., Fusobacterium necrophorum, and Clostridium perfringens susceptible to clindamycin.
For the treatment of superficial pyoderma associated with Staphylococcus pseudintermedius susceptible to clindamycin.
For the treatment of osteomyelitis, caused by Staphylococcus aureus susceptible to clindamycin.
For the treatment of infected wounds and abscesses, and oral cavity infections including periodontal disease, caused by bacteria susceptible to clindamycin.
Do not use in cases of hypersensitivity to the active substance or to any of the excipients or to lincomycin. Do not administer to rabbits, hamsters, guinea pigs, chinchillas, horses and ruminants, because ingestion of clindamycin by these species can cause severe gastro-intestinal disturbance which may result in death.
Special precautions for use in animals
The chewable tablets are flavoured. In order to avoid any accidental ingestion, store tablets out of reach of the animals.
Use of the product should be based on susceptibility testing of the bacteria isolated from the animal. If this is not possible, therapy should be based on local epidemiological information about susceptibility of the target bacteria.
Official, national and regional antimicrobial policies should be taken into account when the veterinary medicinal product is used.
Use of the product deviating from the instructions given in this datasheet may increase the prevalence of bacteria resistant to clindamycin and may decrease the effectiveness of treatment with lincomycin or macrolide antibacterials due to the potential for cross-resistance.
Cross-resistance has been demonstrated among lincosamides (including clindamycin), erythromycin and other macrolides.
In some cases (localised or mild lesions; to prevent recurrence), superficial pyoderma can be treated topically. The need for and duration of systemic antimicrobial treatment should be based on careful consideration of the individual case.
During prolonged therapy of one month or greater, periodic liver and kidney function tests and blood counts should be performed.
Animals with severe renal and/or very severe hepatic disturbances accompanied by severe metabolic aberrations should be dosed with caution and should be monitored by serum examination during high-dose clindamycin therapy.
The use of the product is not recommended in neonates.
Special precautions to be taken by the person administering the veterinary medicinal product to animals
Lincosamides (lincomycin, clindamycin, pirlimycin) may cause hypersensitivity (allergy) reactions. People with known hypersensitivity to lincosamides should avoid contact with the veterinary medicinal product.
Wash hands after handling tablets.
Accidental ingestion may result in gastro-intestinal effects such as abdominal pain and diarrhoea. Care should be taken to avoid accidental ingestion.
In order to reduce the risk of accidental ingestion by children, do not take the tablets out of the blister until ready to administer to the animal. Return part-used tablets into the blister and carton and use at the subsequent administration.
In case of accidental ingestion, particularly by children, seek medical advice immediately and show the package leaflet or the label to the physician.
Adverse reactions
Vomiting and diarrhoea have been observed uncommonly.
Clindamycin uncommonly causes the overgrowth of non-sensitive organisms such as resistant clostridia and yeasts. In cases of superinfection, appropriate measures must be taken according to the clinical situation.
The frequency of adverse reactions is defined using the following convention:
- very common (more than 1 in 10 animals treated displaying adverse reaction(s))
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).
Use during pregnancy and lactation
While high dose studies in rats suggest that clindamycin is not a teratogen and does not significantly affect the breeding performance of males and females, safety in gestating bitches/queens or breeding male dogs/cats has not been established.
Clindamycin crosses the placental and the blood-milk barrier.
Treatment of lactating females can cause diarrhoea in puppies and kittens.
Use only according to the benefit/risk assessment by the responsible veterinarian.
Clindamycin hydrochloride has been shown to have neuromuscular blocking properties that may enhance the action of other neuromuscular blocking agents. The product should be used with caution in animals receiving such agents.
Aluminium salts and hydroxides, kaolin and aluminium-magnesium-silicat complex may reduce the absorption of lincosamides. These digestive substances should be administered at least 2 hours before clindamycin.
Clindamycin should not be used concomitantly with or immediately after erythromycin or other macrolides to prevent macrolide-induced resistance to clindamycin.
Clindamycin may reduce plasma levels of cyclosporine with a risk of lack of activity.
During the simultaneous use of clindamycin and aminoglycosides (e.g.gentamicin), the risk of adverse interactions (acute renal failure) cannot be excluded. Clindamycin should not be used concomitantly with chloramphenicol or macrolides as they antagonise each other at their site of action at the 50S ribosomal sub-unit.
Amounts to be administered and administration route
Oral use.
1. For the treatment of infected wounds and abscesses, and oral cavity infections including periodontal disease in dogs and cats, administer either:
- 5.5 mg/kg of body weight every 12 hours for 7-10 days, or
- 11 mg/kg of body weight every 24 hours for 7-10 days
If no clinical response is seen within 4 days, redetermine the diagnosis.
2. For the treatment of superficial pyoderma in dogs, administer either:
- 5.5 mg/kg of body weight every 12 hours, or
- 11 mg/kg of body weight every 24 hours
Therapy of canine superficial pyoderma is usually recommended for 21 days, with shortening or extension of therapy based on clinical judgement.
3. For the treatment of osteomyelitis in dogs, administer:
- 11 mg/kg of body weight every 12 hours for a minimum of 28 days
If no clinical response is seen within 14 days, the treatment should be stopped and the diagnosis redetermined.
To ensure a correct dosage, body weight should be determined as accurately as possible to avoid under-dosing.
Tablets can be divided into 2 or 4 equal parts to ensure accurate dosing. Place the tablet on a flat surface, with its scored side facing up and the convex (rounded) side facing the surface.
2 equal parts: press down with your thumbs on both sides of the tablet.
4 equal parts: press down with your thumb in the middle of the tablet.
In dogs, oral doses of clindamycin up to 300 mg/kg/day did not result in toxicity. Dogs receiving 600 mg/kg/day of clindamycin developed anorexia, vomiting and weight loss. Vomiting was also recorded in cats dosed at 25 or 50 mg/kg/day. In cases of overdose, discontinue treatment immediately and establish symptomatic treatment.
Pharmacological particulars
Pharmacotherapeutic group: Anti-infectives for systemic use, lincosamides
ATCvet code: QJ01FF01
Pharmacodynamic properties
Mode of action
Clindamycin is a semi-synthetic antibiotic produced by 7(S)-chloro substitution of the 7(R)-hydroxy group of the natural antibiotic produced by Streptomyces lincolnensis var. lincolnensis.
Clindamycin, a mainly time-dependent acting antibiotic, acts by a bacteriostatic mechanism where the drug interferes with protein synthesis within the bacterial cell, thus inhibiting the growth and multiplication of the bacteria.
Clindamycin binds to the 23S ribosomal RNA component of the 50S subunit. This prevents amino acids binding on these ribosomes, and therefore inhibits peptide bond formation. The ribosomal sites are close to those bound by macrolides, streptogramins or chloramphenicol.
Antibacterial spectrum
Clindamycin is a moderate spectrum antimicrobial drug.
Clindamycin has in vitro activity against the following micro-organisms:
- Aerobic Gram-positive cocci, including: Staphylococcus pseudintermedius and Staphylococcus aureus (penicillinase and non-penicillinase producing strains), Streptococcus spp. (except Streptococcus faecalis).
- Anaerobic Gram-negative bacilli, including: Bacteroides spp., Fusobacterium necrophorum.
- Clostridia: Most C. perfringens are susceptible.
MIC data
CLSI clindamycin veterinary breakpoints are available for dogs in Staphylococcus spp. and Streptococci-β-haemolytic group in skin and soft tissue infections: S≤0.5μg/ml; I=1-2µg/ml; R≥4μg/ml (CLSI February 2018).
Type and mechanism of resistance
Clindamycin belongs to the lincosamide group of antibiotics. Resistance can develop to the lincosamides alone, but more commonly cross-resistance occurs among macrolides, lincosamides and streptogramin B antibiotics (MLSB group). Resistance is the result of methylation of adenine residues in the 23S RNA of the 50S ribosomal subunit, which prevents drug binding to the target site. Different bacterial species are able to synthesize an enzyme, encoded by a series of structurally related erythromycin ribosomal methylase (erm) genes. In pathogenic bacteria, these determinants are mostly borne by plasmids and transposons that are selftransferable. The erm genes occur predominantly as variants erm(A) and erm(C) in Staphylococcus aureus and as variant erm(B) in Staphylococcus pseudintermedius, streptococci and enterococci . Bacteria resistant to macrolides but initially susceptible to clindamycin, rapidly develop resistance to clindamycin when exposed to macrolides. These bacteria present a risk of in vivo selection of constitutive mutants. MLSB inducible resistance is not detected by standard in vitro susceptibility testing methods. The CLSI recommends the D-zone test to be routinely performed in veterinary diagnostic laboratories in order to detect clinical isolates with inducible resistance phenotype. Clindamycin use should be discouraged in these patients.
The incidence of resistance to lincosamides in Staphylococcus spp. appears to be wide-ranging in Europe. Recent studies (2010) report an incidence between 25-40%.
Pharmacokinetic properties
Clindamycin hydrochloride is rapidly absorbed from the canine and feline gastrointestinal tract following oral administration. After oral administration of the product to dogs (10.8 mg/kg), bioavailability was 63%.
Serum values:
After oral administration of 10.6 mg/kg body weight to cats, the maximal concentration of 7.2 µg/ml (mean Cmax) is reached within 40 minutes (median Tmax). In dogs, the maximal concentration of 6.1 µg/ml (mean Cmax) is reached within 1 hour (median Tmax) after oral administration of 10.8 mg/kg body weight. The plasma elimination half-life of clindamycin is approximately 5 hours in the cat and 3.5 hours in the dog. No accumulation of bioactivity has been observed in dogs or cats after several oral administrations.
Metabolism and Excretion:
Extensive research of the metabolism and excretion pattern of clindamycin shows that the parent molecule as well as bioactive and bio-inactive metabolites are excreted via the urine and faeces.
Nearly all bioactivity in the serum following oral administration is due to the parent molecule (clindamycin).
Pharmaceutical particulars
Shelf life
Shelf life of the veterinary medicinal product as packaged for sale: 3 years
Shelf life of divided tablets after first opening the immediate packaging: 3 days
Special precautions for storage
This veterinary medicinal product does not require any special storage conditions.
Immediate packaging
Aluminium - Polyamide/Aluminium/PVC blister
Cardboard box of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or 25 blisters of 10 tablets.
Cardboard box containing 10 separate cardboard boxes, each containing 1 blister of 10 tablets.
Not all pack sizes may be marketed.
Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.
Marketing Authorisation Holder (if different from distributor)
Dechra Regulatory BV, Handelsweg 25, 5531 AE Bladel, The Netherlands.
Marketing Authorisation Number
Vm 50406/4004: 55 mg
Vm 50406/4005: 220 mg
Vm 50406/4006: 440 mg
Significant changes
Date of the first authorisation or date of renewal
16 April 2019
Date of revision of the text
September 2023
Any other information
For animal treatment only. To be supplied only on veterinary prescription. Keep out of the sight and reach of children.
Legal category
Legal category: POM-V
GTIN description:​Clindabactin 55 mg Chewable Tablets for Cats and Dogs 10 tablets:
GTIN description:​Clindabactin 220 mg Chewable Tablets for Dogs 10 tablets:
GTIN description:​Clindabactin 440 mg Chewable Tablets for Dogs 10 tablets: